Belpointe Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Belpointe Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7	Closed	-$764	–	3701
2023 Q1	$764	Sell	7 -202	-97%	-$22.3K	﹤0.01%	3523
2022 Q4	$23.8K	Buy	+209	New	+$17.4K	﹤0.01%	2061
2021 Q4	–	Sell	-7,064	Closed	-$774K	–	1280
2021 Q3	$774K	Buy	+7,064	New	+$733K	0.05%	378

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Belpointe Asset Management's HZNP Position: Q2 2023 in Review

Belpointe Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 7 shares — an estimated $764 sold.

Belpointe Asset Management first reported a position in HZNP in Q3 2021 and held it in 3 quarters. The position peaked at $774K in Q3 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Belpointe Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 7 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $764.
Belpointe Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 3 quarters.
Belpointe Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $774K in Q3 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.